We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Small biotech steers HDAC inhibitor to clinic.
- Authors
Ratner, Mark
- Abstract
The article focuses on U.S. approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) in U.S. drug market for treating rare T-cell lymphomas as of September 2014. The topics discussed include market opportunity associated with possible use of HDAC inhibitors to clinic to hematologic and solid tumors, and the role of acetylation of lysine residues on histones in regulating epigenetic gene expressions. Also discussed are several agents targeting epigenetic priming of tumors.
- Subjects
T-cell lymphoma; DRUG approval; HISTONE deacetylase inhibitors; TUMOR treatment; ANTINEOPLASTIC agents; EPIGENETICS; TUMOR genetics; THERAPEUTICS
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 9, p853
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0914-853